<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vsp</journal-id><journal-title-group><journal-title xml:lang="ru">Вопросы современной педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Current Pediatrics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-5527</issn><issn pub-type="epub">1682-5535</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">vsp-719</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES</subject></subj-group></article-categories><title-group><article-title>СОВРЕМЕННЫЕ ПРИНЦИПЫ ПАТОГЕНЕТИЧЕСКОЙ ТЕРАПИИ АТОПИЧЕСКОГО ДЕРМАТИТА У ДЕТЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>PATHOGENETIC THERAPY FOR ATOPIC DERMATITIS IN CHILDREN: CURRENT ISSUES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>Г.И.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>G.I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Московская медицинская академия им. И.М. Сеченова<country>Россия</country></aff><aff xml:lang="en">I.M. Sechenov Moscow Medical Academy<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>07</day><month>09</month><year>2015</year></pub-date><volume>5</volume><issue>2</issue><issue-title>Вопросы современной педиатрии</issue-title><fpage>50</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Смирнова Г., 2006</copyright-statement><copyright-year>2006</copyright-year><copyright-holder xml:lang="ru">Смирнова Г.</copyright-holder><copyright-holder xml:lang="en">Smirnova G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vsp.spr-journal.ru/jour/article/view/719">https://vsp.spr-journal.ru/jour/article/view/719</self-uri><abstract><p>В лекции представлены современные взгляды на рациональную наружную терапию атопического дерматита у детей. Обсуждаются вопросы использования топических противовоспалительных препаратов — содержащих и не содержащих глюкокортикостероиды. среди последних особое внимание уделено Пимекролимусу 1% крему (Элидел, Новартис Фарма, Германия). Показано, что препарат позволяет достигать контроля над симптомами заболевания, особенно при его лёгком и среднетяжелом течении, необходим для профилактики обострений и увеличения длительности ремиссии. </p><p>Ключевые слова: атопический дерматит, дети, наружная терапия, пимекролимус 1% крем.(Вопросы современной педиатрии. – 2006;5(2):50-55)</p></abstract><trans-abstract xml:lang="en"><p>The lecture presents current opinions on the problem of topical treatment of atopic dermatitis in children discussing different topical antiainflamatory drugs with and without corticosteroids. pimecrolimus 1% cream (elidel, novartis pharma, Germany) is specially emphasized among the latter. Pimecrolimus is shown to provide symptom relief and control in mild and moderate cases of atopic dermatitis, so it could become essential in preventing exacerbations and elongation of remission periods of the disease.</p><p>Key words: atopic dermatitis, topical treatment, pimecrolimus 1% cream.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>дети</kwd><kwd>наружная терапия</kwd><kwd>пимекролимус 1% крем</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>topical treatment</kwd><kwd>pimecrolimus 1% cream</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
